[Ip-health] Bill C-13

Baker, Brook b.baker at northeastern.edu
Wed Mar 25 12:43:42 PDT 2020


It would be even better if the legislation also provided exceptions to other exclusivities including data/marketing exclusivity.
Brook

On 3/25/20, 3:20 PM, "Ip-health on behalf of James Love" <ip-health-bounces at lists.keionline.org on behalf of james.love at keionline.org> wrote:

    The Canada bill is already law, as part of a larger package of measures.
    The U.S.  House Democrats and Senate GOP both avoiding doing anything about
    patent issues, but the German and Canadian legislators say this as an
    important issue to be addressed.
    
    The Canada bill addressed patent issues not only for tests, drugs or
    vaccines,  but for any patent that would be useful.
    
    The following is an email from Jody Cox, from the Canadian Generics and
    Biosimilars associations.
    
    Jamie
    
    ------------------------------------------------
    On Wed, Mar 25, 2020 at 2:58 PM Jody Cox wrote:
    
    Hi James,
    
    I am responding to your interest in Bill C-13, An Act respecting certain
    measures in response to COVID-19.
    
    This is Canada’s COVID-19 aid package, which was passed into law this
    afternoon. The text of Bill C-13 is attached.
    
    A media report providing some background on the aid package is available at
    https://nam05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.cbc.ca%2Fnews%2Fpolitics%2Fcovid19-coronavirus-ottawa-hill-economic-legislation-1.5509178&data=02%7C01%7Cb.baker%40northeastern.edu%7Cd3ade795ef6f4045c90108d7d0f19276%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637207608278642088&sdata=fXd0FXbgSOwXT9ihCOBA7G1aooXKFhoohsmeXwGf1kY%3D&reserved=0
    
    The summary to Bill C-13 states:
    
    "Part 12 amends the Patent Act to, among other things, provide that the
    Commissioner must, on the application of the Minister of Health, authorize
    the Government of Canada and any person specified in the application to
    make, construct, use and sell a patented invention to the extent necessary
    to respond to a public health emergency that is a matter of national
    concern." The provision is applicable to all patents.
    
    The Canadian Generic Pharmaceutical Association (CGPA) supports this
    measure. "The ability of a country to issue compulsory licences for
    medicines and other urgently needed items to respond to a health crisis is
    not a novel approach, and is embedded in international trade agreements
    such as the WTO Agreement on the Trade-Related Aspects of Intellectual
    Property Rights (TRIPS). This is a prudent and reasonable precautionary
    measure," said Jim Keon, President of the Canadian Generic Pharmaceutical
    Association.
    
    Hope this provides some useful background.
    Best regards,
    
    Jody
    
    Jody Cox, Vice President, Federal and International Affairs
    Canadian Generic Pharmaceutical Association (CGPA)
    https://nam05.safelinks.protection.outlook.com/?url=www.canadiangenerics.ca&data=02%7C01%7Cb.baker%40northeastern.edu%7Cd3ade795ef6f4045c90108d7d0f19276%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637207608278642088&sdata=1dDfnQp%2F0xO9cOUMmV3pOoYI8Vv%2FV6itSpd83ozALos%3D&reserved=0 | https://nam05.safelinks.protection.outlook.com/?url=www.generiquescanadiens.ca&data=02%7C01%7Cb.baker%40northeastern.edu%7Cd3ade795ef6f4045c90108d7d0f19276%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637207608278652078&sdata=P2nYFv4A6BxVSRgcUdQ%2FOqEG2MWV9iebaTyxTNgkvz8%3D&reserved=0
    @CdnGenerics | @AcmgQuebec
    
    Jody Cox, Vice President, Biosimilars Canada
    https://nam05.safelinks.protection.outlook.com/?url=www.biosimilarscanada.ca&data=02%7C01%7Cb.baker%40northeastern.edu%7Cd3ade795ef6f4045c90108d7d0f19276%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637207608278652078&sdata=7os7SmTsW9WLr7zvpOQBTGLJ3fG32j%2Ba2BKaOySyE%2Fk%3D&reserved=0 | https://nam05.safelinks.protection.outlook.com/?url=www.biosimilairescanada.ca&data=02%7C01%7Cb.baker%40northeastern.edu%7Cd3ade795ef6f4045c90108d7d0f19276%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637207608278652078&sdata=CLuSfSkm6T9ju0l9Wo5mabYJ9PEYZkuHvVV4%2BTCX5tY%3D&reserved=0 | @CdnBiosimilars
    _______________________________________________
    Ip-health mailing list
    Ip-health at lists.keionline.org
    https://nam05.safelinks.protection.outlook.com/?url=http%3A%2F%2Flists.keionline.org%2Fmailman%2Flistinfo%2Fip-health_lists.keionline.org&data=02%7C01%7Cb.baker%40northeastern.edu%7Cd3ade795ef6f4045c90108d7d0f19276%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637207608278652078&sdata=zn8zJbTMD2qeY%2BnXO6Cl80ElQriPm23JRLnqyADLWeU%3D&reserved=0
    



More information about the Ip-health mailing list